Key insights
- Whitehawk Therapeutics (WHWK) announced an $87.5 million private placement to extend its cash runway into the second half of 2028. The funds will be used for working capital and advancing its antibody drug conjugate pipeline. While the financing alleviates immediate cash burn concerns, the stock dilution may exert slight downward pressure.
MORRISTOWN, N.J. - Whitehawk Therapeutics Inc. (NASDAQ:WHWK) announced today it has entered into a securities purchase agreement for a private investment in public equity financing expected to generate gross proceeds of approximately $87.5 million before deducting placement agent fees and other expenses.
The clinical-stage oncology therapeutics company is selling 4,330,866 shares of common stock at $3.92 per share and pre-funded warrants to purchase 17,991,021 shares at $3.9199 per warrant, according to a press release statement. The pre-funded warrants have an exercise price of $0.0001 per share. The financing comes as the stock trades near its current market capitalization of $193.76 million, having delivered a remarkable 138% return over the past year.
The financing includes participation from existing investors including Avoro Capital, QVT, Coastlands Capital, KVP Capital, ADAR1 Capital Management, Acuta Capital Partners, StemPoint Capital LP, Invus, and members of the company’s executive team.
The transaction is expected to close Thursday, subject to customary closing conditions.
Whitehawk stated it intends to use the net proceeds, together with existing cash, cash equivalents and marketable securities, for working capital and general corporate purposes, including advancing its antibody drug conjugate pipeline and related development activities. The company said proceeds from the financing, combined with existing cash, cash equivalents and marketable securities, are expected to extend its cash runway into the second half of 2028. This capital infusion addresses a critical need, as InvestingPro Tips indicate the company is quickly burning through cash, though it maintains a strong current ratio of 11.36 and holds more cash than debt on its balance sheet. According to InvestingPro analysis, WHWK appears undervalued at current levels, with 10 additional ProTips available to subscribers, along with comprehensive Pro Research Reports covering this and 1,400+ other US equities.
Jefferies and Leerink Partners are serving as lead placement agents for the financing. Oppenheimer & Co., Citizens Capital Markets and Jones are also acting as placement agents.
The securities are being sold in a transaction not involving a public offering and have not been registered under the Securities Act of 1933.
Whitehawk Therapeutics focuses on developing antibody drug conjugate cancer treatments.
In other recent news, Whitehawk Therapeutics has reaffirmed its Market Outperform rating from Citizens, with a price target set at $8.00, following its first-quarter 2026 earnings report and corporate updates. The biotechnology company recently presented preclinical data on three antibody-drug conjugate (ADC) candidates at the American Association for Cancer Research Annual Meeting 2026. These candidates, identified as HWK-007, HWK-016, and HWK-206, showed tumor regressions in various cancer models at low doses. Whitehawk also presented data on the MUC16 target for ovarian cancer ADCs at the Society of Gynecologic Oncology 2026 Annual Meeting. This analysis, conducted with Tempus AI, highlighted significant MUC16 expression in ovarian and endometrial cancers. Notably, MUC16 expression was found to be 2- to over 100-fold higher than other ADC targets in ovarian cancer. Citizens initiated coverage on Whitehawk with a Market Outperform rating, basing its valuation on cash per share and platform value analysis. Whitehawk is actively developing ADCs targeting PTK7, MUC16, and SEZ6.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.